PAVMED INC. (NASDAQ:PAVM) Files An 8-K Entry into a Material Definitive Agreement

PAVMED INC. (NASDAQ:PAVM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

On January 19, 2018, PAVmed Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc., as underwriter (the “Underwriter”), relating to the sale to the public (the “Offering”) of (i) 2,415,278 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) and (ii) up to 362,292 shares of Common Stock (the “Option Shares”, and together with the Firm Shares, the “Shares”), which may be issued by the Company upon the exercise of an over-allotment option granted to the Underwriter.

Dawson James Securities, Inc. is acting as sole underwriter in the Offering.

to the Underwriting Agreement, the Company agreed to sell and issue the Shares at a public offering price of $1.80 per share. The Underwriter will purchase the Shares at a discount of $0.144 per share, representing 8% of the public offering price, for an aggregate discount of $347,800, or $399,970 assuming the over-allotment option is exercised in full. After deducting underwriting discounts and estimated expenses payable by the Company associated with the Offering, the net proceeds to the Company are expected to be approximately $3.9 million, or $4.5 million assuming the over-allotment option is exercised in full.

The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. The Offering is expected to close on or about January 23, 2018, subject to customary closing conditions.

The Offering is being made to a prospectus supplement dated January 19, 2018 and an accompanying base prospectus, which are to be filed as part of the Company’s “shelf” Registration Statement on Form S-3 (File No. 333-220549), which was declared effective on October 6, 2017.

The Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by reference to such exhibit.

The Underwriting Agreement has been included to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties, and covenants contained in the Underwriting Agreement were made solely for purposes of such agreement, as of specific dates, for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of such agreement.

Item 8.01. Other Events.

On January 18, 2018, the Company issued a press release announcing the Offering. On January 19, 2018, the Company issued a press release announcing that it had signed the Underwriting Agreement and priced the Offering. The press releases are attached to this Current Report as Exhibits 99.1 and 99.2, respectively.

Item 9.01. Financial Statement and Exhibits.

(d)Exhibits:


PAVmed Inc. Exhibit
EX-1.1 2 ex1-1.htm   Exhibit 1.1   UNDERWRITING AGREEMENT   January 19,…
To view the full exhibit click here

An ad to help with our costs